Consistency of Immunogenicity and Non Inferiority of Three Production Lots of GSK Biologicals' Candidate Malaria Vaccine in Children.
Latest Information Update: 31 Aug 2023
At a glance
- Drugs GSK 257049 (Primary)
- Indications Malaria
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 25 May 2012 Actual patient number 327 added as reported by ClinicalTrials.gov.
- 25 May 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.
- 25 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.